PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGenome engineering company launches with $43 million investments

BioNews

Genome engineering company launches with $43 million investments

Published 29 November 2013 posted in News and appears in BioNews 733

Author

Dr Rachel Montgomery

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A biotech start-up that will develop genome-editing therapies has received US $43 million investment from three venture capital firms...

A biotech
start-up that will develop genome-editing therapies has received US $43 million investment from three venture capital firms.

Editas Medicine,
based in Massachusetts, plans to develop a new class of drugs that can
precisely correct disease-causing mutations in DNA, using a technology called
CRISPR/Cas9.

CRISPR can be used to edit single
base pairs and larger stretches of DNA, leading researchers to believe its versatility
can be used to target any mutation.

'The way to think about it
is molecular surgery… you can go in and make
changes to the DNA', Dr J Keith Joung, co-founder of Editas Medicine, told the Boston Globe. 'If there's a
defect, you can fix it; if there's a missing piece, you can put the missing
piece in'.

CRISPR/Cas9 is a gene-editing system initially
identified in bacteria, where it protects against viruses (see BioNews 730). A guide RNA
molecule brings the Cas9 protein to a specific stretch of DNA, which it then
cuts in a precise way. Unwanted DNA can
therefore be 'deleted' and replaced with versions of DNA to correct the faulty gene.

Dr Douglas Cole is a general partner at Flagship Ventures, one of the venture
capital firms alongside Polaris Partners and Third Rock Ventures that have invested
in Editas. He said: 'The gene editing approaches on which Editas is based
represent some of the most exciting and promising scientific breakthroughs in
recent years, making it possible, for the first time, to correct the genomic
defects responsible for a broad range of diseases'.

Editas Medicine has
not announced the conditions they will be aiming to treat. But their focus will
be on diseases that are proving especially hard to treat with traditional gene
therapy or gene knock-down efforts that do not actually remove the faulty gene
from cells. These traditional efforts have associated safety concerns and cannot
correct diseases that arise from faulty genes producing toxic proteins; such is
the case in Huntington's Disease.

Therapies based on CRISPR could overcome
these problems by precisely and accurately replacing the
faulty gene in its normal chromosomal region.

However, there
are technological and ethical barriers still to overcome, in addition to the
normal clinical trials, so it is likely to be years before a precise
genome-editing therapy will be available on the market.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 February 2016 • 2 minutes read

Editas goes public despite CRISPR patent battle

by Cait McDonagh

A biotechnology company co-founded by two leading scientists involved in developing the genome-editing technology, CRISPR/Cas9, has gone public, raising over $94 million in its initial share offering...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 March 2015 • 2 minutes read

Embryo gene-editing is unsafe and unethical, say gene-editing scientists

by Meghna Kataria

Scientists have called for a worldwide moratorium on the use of the gene-editing technique CRISPR/Cas9 in human embryos and germ cells...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 November 2013 • 3 minutes read

Accurate editing of human DNA now possible, say scientists

by Dr Anna Cauldwell

A molecular technique that enables any part of the human genome to be altered with extreme precision has been hailed by scientists as a breakthrough in genetics...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
1 November 2013 • 2 minutes read

Clinical-stage gene therapy company launched

by Dr Naqash Raja

The Children's Hospital of Philadelphia has invested US $50 million in a biotech start-up in an effort to commercialise gene therapy...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
2 November 2012 • 2 minutes read

Gene therapy approved in Europe for first time

by Dr Lucy Spain

The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Gene 'editing' technique shows promise

by BioNews

A gene therapy technique that repairs faulty genes by 'editing' their DNA could lead to new treatments for inherited blood disorders and HIV, say US researchers. The approach could help address safety concerns over current gene therapy methods, many of which rely on specially adapted viruses to deliver working genes...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« The alcohol gene? Mice with mutation hit the bottle

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

15 August 2022 • 2 minutes read

Call to end ban on HIV-positive partner gamete 'donation'

15 August 2022 • 2 minutes read

Melanoma invades new tissues using nerve cell gene

15 August 2022 • 2 minutes read

Exceeding alcohol limits could damage DNA and accelerate ageing

15 August 2022 • 2 minutes read

Blood cell gene mutations affect mitochondria, increasing cardiovascular disease risk

15 August 2022 • 2 minutes read

Jumping gene helps immune system fight viruses

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856